Cover Image

Breo Ellipta(氣喘):市場預測與分析

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 316075
出版日期 內容資訊 英文 53 Pages
Back to Top
Breo Ellipta(氣喘):市場預測與分析 Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023
出版日期: 2014年08月31日 內容資訊: 英文 53 Pages



Breo Ellipta(歐洲是以Relvar Ellipta之名上市),是糖酸Fluticasone和vilanterol trifenatate的FDC(固定劑量複方藥物),用於同時需要ICS(吸入用類固醇藥)和LABA(長效型β2刺激藥)的氣喘患者的維持療法上。使用上利用Ellipta這個新的DPI(乾粉吸入器)。配合成分之一的糖酸Fluticasone是具有潛在消炎效果的合成三氟化皮質類固醇,可減為一日只要給藥一次,這關係到患者依從性及治療成績的改善。糖酸Fluticasone更朝向比GSK更獨立型的ICS治療藥方向開發。

本報告提供氣喘治療藥之一──Breo Ellipta的全球市場相關分析,提供氣喘概要和治療方法,競爭的企業、藥品概要,市場競爭概況,Breo Ellipta的商品資訊(特色·功效·安全性等),全球主要國家的市場銷售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 預定公開的相關報告書

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
    • 預後
    • 生活品質(QoL)
  • 症狀

第4章 疾病管理

  • 診斷及治療概要
    • 診斷
    • 治療指南,臨床診療及代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要
  • 策略性競爭評估

第6章 Breo Ellipta(糖酸Fluticasone/vilanterol trifenatate)

  • 概要
  • 有效性
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄



GlobalData has released its new PharmaPoint Drug Evaluation report, "Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Breo Ellipta (or Relvar Ellipta in Europe) is an FDC of fluticasone furoate and vilanterol trifenatate for the maintenance treatment of asthma in patients who need both an ICS and a LABA. Breo is dosed via a new DPI device, Ellipta. Breo's pharmacodynamics allow for once-daily administration, and it is going to be the first FDC that allows for once-daily administration for the maintenance treatment of asthma. This is due to its ICS component, fluticasone furoate, which is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity that can be dosed once a day, thus improving patient compliance and treatment outcomes. Fluticasone furoate is also being developed by GSK as a stand-alone ICS therapy.


  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Breo Ellipta including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Breo Ellipta for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Breo Ellipta performance
  • Obtain sales forecast for Breo Ellipta from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Breo Ellipta (fluticasone furoate/vilanterol trifenatate)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Asthma Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Author/Reviewer
    • 7.6.3. Reviewer
    • 7.6.4. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Leading Treatments for Asthma, 2014
  • Table 7: Product Profile - Breo Ellipta
  • Table 8: Efficacy - Breo Ellipta Versus Flovent
  • Table 9: Safety - Breo Ellipta Versus Flovent
  • Table 10: Breo Ellipta SWOT Analysis, 2014
  • Table 11: Global Sales Forecast ($) for Breo Ellipta, 2013-2023
  • Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
Back to Top